Table 3   Bioequivalence Analysis of Paclitaxel Pharmacokinetic Area Under the Concentration-Time Curve Parameters (PK Analysis Set)

PK Parameter	Geometric mean ratio (%)[a]	90% CI	Intra subject CV%
$AUC_{0-\infty}$	89.5	83.9, 95.5	16.1
AUC_{0-t}	88.3	82.6, 94.4	16.7

a Ratio (oral paclitaxel 615 mg/m^2 over 3 consecutive days with encequidar 15mg days 1-3 / 80 mg/m^2 IV paclitaxel) of the least square means from the ANOVA of the log-transformed $AUC_{0-\infty}$ of paclitaxel.